OxThera Strengthens Patent Portfolio for Orphan Disease – Primary Hyperoxaluria

barbara.lempert STOCKHOLM, June 4, 2013 /PRNewswire/ — OxThera AB has been granted three Japanese patents during 2012 and 2013. The patents will secure the pharmaceutical composition ...

AstraZeneca gets mixed results in Nexium patent fight with Hanmi

Eric Palmer AstraZeneca has gotten mixed results in a lawsuit agreement as it continues to try to hold generics at bay in the U.S. for its blockbuster stomach drug Nexium. It said today ...

Shire Settles Patent Infringement Lawsuit Against Teva Concerning Intuniv

barbara.lempert Shire Settles Patent Infringement Lawsuit Against Teva Concerning INTUNIV® PHILADELPHIA, May 31, 2013 /PRNewswire/ — Shire LLC has settled its litigation against ...

Lpath Granted Key U.S. Patent Related to Ocular Drug Program, iSONEP

barbara.lempert Patent Provides Coverage for Lpath’s Anti-S1P Antibody in the Treatment of a Wide Variety of Ocular Disorders, Including Wet AMD SAN DIEGO, May 30, 2013 (GLOBE ...

Medigene Receives Further European Patent on EndoTAG-1

barbara.lempert Martinsried/Munich, 29 May 2013. Medigene AG (Frankfurt, Prime Standard; MDG) announced today that the European Patent Office has granted a further patent which protects ...

When is it fair to slap a ‘pay for delay’ label on a patent settlement?

Tracy Staton Are antitrust regulators unfairly targeting BIg Pharma's patent settlements? As the debate rages on–and continues to spread–more experts and pharma execs ...

Behold the patent cliff: U.S. drug market shrinks for first time

Tracy Staton U.S. drug spending dropped last year. While that may be welcome news for healthcare budgets, it's not so good for branded drugmakers. It may not be so good for patients, ...

Behold the patent cliff: U.S. drug market shrinks for first time

Tracy Staton U.S. drug spending dropped last year. While that may be welcome news for healthcare budgets, it's not so good for branded drugmakers. It may not be so good for patients, ...

Eli Lilly slugs it out with J&J on Alzheimer’s drug patent claim

John Carroll With a new late-stage study being prepped for the Alzheimer's drug solanezumab, Eli Lilly found itself in a London courtroom this week defending itself against a patent ...

Bayer to face new Yaz rivals as patent goes up in flames

Tracy Staton Bayer has taken another hit on its birth-control pill Yaz. After taking a $ 500 million charge against 2012 earnings for Yaz and Yasmin-related litigation, the German ...

OxyContin patent expires Tuesday but FDA under pressure to stall generics

Eric Palmer Purdue's original patent on the superpotent and often abused painkiller OyxContin expires tomorrow, and drugmakers like Teva Pharmaceutical Industries ($ TEVA) are ...

Eli Lilly to lay off hundreds in sales as Cymbalta nears edge of patent cliff

Here is a business reality that hundreds of Eli Lilly ($ LLY) sales employees are going to have to align themselves with quite soon: They are about to lose their jobs. With its best-selling ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS